MERCK MEVACOR MARS STUDY's ANTI-ATHEROMA FINDINGS ARE FOCUS OF NEW PRODUCT PROMOTION; PRAVACHOL STUDY IN PATIENTS POST-MI IS ONGOING AT KAISER
Executive Summary
Merck is exploring a new Mevacor (lovastatin) promotional campaign emphasizing the cholesterol-lowering drug's anti-atheroma capabilities and new labeling, Merck U.S. Human Health Care Division President Richard Lane said at the company's 1994 business briefing Feb. 11 in New York City.